Hoth Therapeutics Inc
Company Profile
Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USAT: +1 646 756-2997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,063.40 | 33.90 | 0.38% |
CAC 40 | 7,762.23 | 65.22 | -0.83% |
DAX 40 | 23,394.23 | 272.58 | -1.15% |
Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
FTSE 100 | 9,207.38 | 43.05 | -0.47% |
HKSE | 26,484.68 | 33.97 | -0.13% |
NASDAQ | 22,497.86 | 75.62 | -0.33% |
Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
S&P 500 | 6,637.97 | 18.95 | -0.28% |
S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
SSE Composite Index | 3,853.30 | 0.34 | -0.01% |